| Q24651931 | A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs |
| Q37598267 | AVE8062: a new combretastatin derivative vascular disrupting agent. |
| Q37597936 | An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors |
| Q36287729 | Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). |
| Q44580396 | Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo |
| Q78594497 | Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 |
| Q44412196 | Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo |
| Q44558813 | Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). |
| Q36146900 | Disrupting tumour blood vessels |
| Q36900208 | Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. |
| Q33183693 | Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. |
| Q55031551 | Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. |
| Q38796352 | Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700) |
| Q48300160 | Maintaining unperturbed cerebral blood flow is key in the study of brain metastasis and its interactions with stress and inflammatory responses. |
| Q38602109 | Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis |
| Q44507596 | Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium |
| Q89587161 | Necrosis in the Tumor Microenvironment and Its Role in Cancer Recurrence |
| Q34293629 | New agents in cancer clinical trials |
| Q38979348 | Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface |
| Q34829230 | Role of the cytoskeleton in formation and maintenance of angiogenic sprouts |
| Q37958731 | Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism |
| Q44501064 | Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization. |
| Q40654786 | Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. |
| Q55040537 | TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. |
| Q34572069 | Targeting tumour vasculature: the development of combretastatin A4. |
| Q56450717 | The Vascular-Disrupting Agent Combretastatin Impairs Splitting and Sprouting Forms of Physiological Angiogenesis |
| Q34680614 | The biology of the combretastatins as tumour vascular targeting agents |
| Q52627703 | The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. |
| Q38118663 | Tubulin-interactive stilbene derivatives as anticancer agents. |
| Q46614854 | Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth |
| Q52614294 | Tumor environment changed by combretastatin derivative (Cderiv) pretreatment that leads to effective tumor targeting, MRI studies, and antitumor activity of polymeric micelle carrier systems. |
| Q54975278 | Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. |
| Q37280244 | Tumour vascular disrupting agents: combating treatment resistance |
| Q79202325 | Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response |
| Q35805639 | Vascular-targeting therapies for treatment of malignant disease. |